Results
|
161.
|
|
|
162.
|
|
|
163.
|
|
|
164.
|
|
|
165.
|
|
|
166.
|
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. [electronic resource] by
- Cummings, J
- Zweifel, M
- Smith, N
- Ross, P
- Peters, J
- Rustin, G
- Price, P
- Middleton, M R
- Ward, T
- Dive, C
Producer: 20120723
In:
British journal of cancer vol. 106
Availability: No items available.
|
|
167.
|
|
|
168.
|
|
|
169.
|
|
|
170.
|
|
|
171.
|
|
|
172.
|
|
|
173.
|
5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. [electronic resource] by
- Rustin, G J S
- Bradley, C
- Galbraith, S
- Stratford, M
- Loadman, P
- Waller, S
- Bellenger, K
- Gumbrell, L
- Folkes, L
- Halbert, G
Producer: 20041116
In:
British journal of cancer vol. 88
Availability: No items available.
|
|
174.
|
|
|
175.
|
|
|
176.
|
|
|
177.
|
|
|
178.
|
|
|
179.
|
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. [electronic resource] by
- Vasey, P A
- Gore, M
- Wilson, R
- Rustin, G
- Gabra, H
- Guastalla, J-P
- Lauraine, E P
- Paul, J
- Carty, K
- Kaye, S
Producer: 20080610
In:
British journal of cancer vol. 98
Availability: No items available.
|
|
180.
|
|